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Abstract A key hallmark of cancer cells is their altered me-
tabolism, known as Warburg effect. Lactate dehydrogenase A
(LDHA) executes the final step of aerobic glycolysis and has
been reported to be involved in the tumor progression. How-
ever, the function of LDHA in prostate cancer has not been
studied. In current study, we observed overexpression of
LDHA in the clinical prostate cancer samples compared with
benign prostate hyperplasia tissues as demonstrated by immu-
nohistochemistry and real-time qPCR. Attenuated expression
of LDHA by siRNA or inhibition of LDHA activities by FX11
inhibited cell proliferation, migration, invasion, and promoted
cell apoptosis of PC-3 and DU145 cells. Mechanistically, de-
creased Warburg effect as demonstrated by reduced glucose
consumption and lactate secretion and reduced expression of
MMP-9, PLAU, and cathepsin B were found after LDHA
knockdown or FX11 treatment in PC-3 and DU145 cells.
Taken together, our study revealed the oncogenic role of
LDHA in prostate cancer and suggested that LDHA might
be a potential therapeutic target.
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Introduction
Although great advances in medical management and screen-
ing, prostate cancer (PC) remains a leading cause of morbidity
and mortality in men [1]. About 15 % of prostates contain
islands of cancer at the age of 50 and nearly 100 % by 80
[2]. Nowadays, the chief treatment for PC is androgen depri-
vation therapy; however, patients on this regime eventually
relapse into hormone-refractory prostate cancer. An enhanced
tumor microenvironment that favors tumor progression is
formed during the critical switch of PC to androgen indepen-
dence and distant metastasis [3]. Therefore, it is urgent to
identify key signaling events driving the tumor microenviron-
ment to find novel therapeutic targets for PC.
Cancer cells take up glucose and transform it to lactate even
under aerobic conditions, known as the Warburg effect. Suf-
ficient amounts of nucleotides, proteins, and lipids derived
from this type of glucose metabolism are required for cancer
cell rapid growth and division [4]. Critical to this highly gly-
colytic phenotype is lactate dehydrogenase A (LDHA), which
catalyses the last step of anaerobic glycolysis. Abnormally
expression of LDHA has been observed in many human can-
cers, such as pancreatic cancer [5], hepatocellular carcinoma
[6], and breast cancer [7]. Inhibition of LDHA reduced cell
malignant transformation and remarkably delayed tumor for-
mation, indicating that the underlying role of LDHA in tumor
initiation or maintenance [8]. Several mechanisms by which
LDHA suppression induces inhibition of tumor progression
are revealed. In lymphoma, reduction of LDHA induces oxi-
dative stress and alters cellular energy metabolism, which ul-
timately contributes to cell death [9]. In breast cancer, LDHA
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knockdown suppresses tumorigenicity through induction of
oxidative stress mediated mitochondrial pathway apoptosis
[10]. In PC, overexpressed lactate dehydrogenase 5 isoen-
zyme has been reported and confers prostate cancer with re-
sistance of to radiotherapy [11]. However, little is known the
expression pattern of LDHA and its underlying roles in PC.
In the present study, we firstly detected the expression of
LDHA in PC and BPH tissues. Next, cellular functions of
LDHAwere analyzed in PC-3 and DU145 cells when LDHA
expression was suppressed or LDHA activity was inhibited.
Moreover, LDHA-dependent mechanisms involved in the
progression of PC were also analyzed.
Materials and methods
Preparation of reagents and cell culture
FX11 (Merck Millipore, Germany) was dissolved in
dimethylsulfoxide (DMSO) and further diluted to preferable
concentrations in culture medium before use. Human prostate
cancer cell lines 22Rv1, DU145, PC-3, and LNCaP were all
purchased from Cell Bank of the Chinese Academy of Sci-
ences. All cells were cultured in DMEM specific medium
supplemented with 10 % (v/v) fetal calf serum at 37 °C in a
humidified incubator under 5 % CO2 condition.
Clinical tissue samples and immunohistochemistry
Twenty freshly frozen PC tissues and 12 benign prostate
hyperplasia (BPH) tissues were recruited from Department
of Urology, Guangdong General Hospital, China. All tissue
samples were obtained with informed consent and approved
by the ethics committee of Guangzhou Municipality. A tis-
sue microarray containing 64 cases of PC tissues and 11
cases of BPH tissues were purchased from Xi-an Alenabio
Inc. (China). After deparaffinizing, rehydrating, antigen re-
trieval, and neutralization of endogenous peroxidase, tissue
sections were blocked with blocking serum, followed by
incubation with primary antibody (LDHA, Proteintech)
overnight at 4 °C. After washing in phosphate-buffered sa-
line (PBS) for three times, the sections were incubated with
HRP-labeled anti-rabbit secondary antibody. The reaction
products were visualized with 3,3′-diaminobenzidine tetra-
hydrochloride (DAB) and counterstained by hematoxylin.
Scoring was conducted on a scale of 0–3: 0–10 % scored
0; 10–35 % scored 1; 36–70 % scored 2; and more than
70 % scored 3. Scored at 0 and 1 was defined as low ex-
pression group, while 2 and 3 was defined as high expres-
sion group. The scoring by the pathologists was done in a
blinded manner.
siRNA transfection
PC-3 cells were transfected specific siRNAs targeting LDHA
as well as a negative control (GenePharma, Shanghai, China).
Transfection was accomplished by seeding 2×105 cells into a
six-well plate, and after 24 h, the medium was aspirated and
incubated with transfection complex according to the manu-
facturer’s protocol. The interference efficiency was detected
by Western blotting, and cell populations with lowest LDHA
expression were used for subsequent experiments.
Real-time quantitative PCR
Total RNA was isolated from cells or frozen tissue samples
using TRIzol reagent (Invitrogen) according to the manufac-
turer’s instructions. Reverse transcription was performed
using the PrimeScript RT-PCR system (Takara, Japan). Then
1 μg cDNA was quantified by real-time PCR with SYBR
Green Master Mix (Takara, Japan). Specific primer sequences
used were as follows: MMP9: forward 5′-GGGACGCAGA
CATCGTCATC-3′, reverse 5′-TCGTCATCGTCGAAATGG
GC-3′; PLAU: forward 5′- GCTTGTCCAAGAGTGCAT
GGT -3′, reverse 5′-CAGGGCTGGTTCTCGATGG-3′; ca-
thepsin B: forward 5′-AGAGTTATGTTTACCGAGGACC
T-3′, reverse 5′-GATGCAGATCCGGTCAGAGA-3′. The ex-
pression level of gene analyzed in this study was standardized
using the expression level of β-actin to obtain a relative level
of gene expression.
Western blotting analysis
Whole cell extracts were prepared using RIPA buffer supple-
mented with protease inhibitor (Beyotime, China). Protein
lysates were separated by SDS-PAGE and target proteins were
probed by Western blotting with antibodies (LDHA and β-
actin, Proteintech). Then, the membranes were consecutively
incubated with HRP-conjugated secondary antibodies
(Abmart, China). The immunoreactive proteins were visual-
ized by ECL Plus kit (Millipore Corporation, Billerica).
Cell migration and invasion assays
Migration and invasion assay was performed with 8.0-μm
pore inserts (Millipore, USA) in 24-well plate. For migration
assay, 20,000 cells were seeded into the upper compartment of
the transwell inserts. The invasion assay was performed with
matrigel-coated filters (BD Bioscience, USA). Cells were
allowed to incubate for 24 and 48 h, respectively. Migrated
and invaded were fixed and stained by 0.1 % (w/v) crystal
violet. Each experiment was performed in triplicate.
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Cell viability assay
Cell viability was evaluated by Cell Counting Kit-8 (CCK-8,
Dojindo, Japan) following the manufacturer’s protocols.
Briefly, 3000 cells were resuspended and seeded into a 96-
well plate supplemented in the presence of 10 % FBS and
cultured overnight. The next day, the LDHA knockdown cells
or FX11-treated cells was incubated with CCK8 for 1 h and
the absorbance was measured at 450 nm using a multifunc-
tional microplate reader (Tecan). This experiment was done in
quadruplicate cells.
Apoptosis assay
Cells under apoptotic condition were analyzed by Annexin V/
PI staining. Briefly, cells with small interfering (RNA) siRNA
or FX11 treatment were seeded in six-well plates at 3×105
cells per well in the absence of FBS for 48 h. Then, cells were
harvested and labeled with FITC-conjugated Annexin V and
propidium iodide (BD Pharmingen) following the manufac-
turer’s instructions. The apoptotic cells were measured by
flow cytometry. The caspase-3/7 activity assay was performed
at 48 h after serum deprivation according to manufacturer’s
instructions (Promega)
Measurements of lactate production and glucose
consumption
Cells were cultured in fresh phenol red-free media and the
culture media were collected in the first 24 h after siRNA or
FX11 treatment. The glucose and glutamine concentration in
the culture media are 5 and 2 mM, respectively. The lactate
and glucose levels were measured by using lactate assay kits
(Biovision) or glucose assay kits (Life Technologies),
respectively.
Statistical analysis
Data were presented as the means±standard error of the mean
(SEM). Statistical analyses and graphical representations were
performed with SPSS 16.0 (SPSS Inc., Chicago, USA) and
GraphPad Prism 5 (San Diego, CA) software. Cell viability
assay was analyzed by one-way ANOVA. And, the Student’s t
Fig. 1 Altered expression of LDHA was observed in PC. a
Representative images of the LDHA expression in benign prostate
hyperplasia (BPH) and pancreatic cancer (PC); scale bar: 50 μm. b In-
creased LDHA protein expression in 11 BPH tissues and 74 PC tissues
were detected by immunohistochemistry. c Increased LDHA mRNA ex-
pression in 12 BPH tissues and 20 PC tissues were detected by quantita-
tive real-time PCR. d LDHA expression in Singh prostate grouped by
normal prostate gland (1, n=50) and prostate cancer (2, n=52) derived
from Oncomine database. e LDHA expression in Tomlins prostate
grouped by no value (0, n=27), BPH (1, n=11), prostatic intraepithelial
neoplasia (2, n=13), and prostate cancer (3, n=49) derived from
Oncomine database. g Expression level of LDHA in four PC cell lines,
tubulin amounts were measured as a control
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test was used for comparison between groups in other data.
Values of P<0.05 were considered statistically significant.
Results
Altered expression of LDHAwere observed in PC
To identify the expression pattern of LDHA in PC, a tissue
microarray (TMA) containing 64 cases of PC specimens and
11 cases of BPH samples was analyzed using immunohisto-
chemical staining. Higher LDHA expression was observed in
75% (48/64) of PC cases, while 18.2% (2/11) in BPH cases, the
difference was significant (Fig. 1a, b). In addition, 20 cases of
PC tissues and 12 cases of BPH tissues were collected to detect
messenger RNA (mRNA) expression of LDHA using real-time
quantitative PCR. We observed that LDHA mRNA expression
was significantly elevated in PC tissues in relative to BPH sam-
ples (Fig. 1c). And, data from Oncomine database further con-
firmed this phenomenon. As shown in Fig. 1d, e, although with-
out significant alternations in prostatic intraepithelial neoplasia,
overexpressed LDHAwas more commonly observed in prostate
cancer. Furthermore, the expression level of LDHA in four PC
cell lines was analyzed by Western blotting (Fig. 1f). To further
analyze the possible functions of LDHA in PC, we selected the
cell line with higher LDHA expression, PC-3 and DU145 cells,
for further investigation.
Silencing of LDHA by siRNAs inhibits cell proliferation,
migration, and invasion and increases cell apoptosis
in vitro
The level of endogenous LDHA expression in PC-3 and
DU145 cells after targeted siRNA treatment was examined
by Western blotting (Fig. 2a). Given that LDHA expression
was significantly decreased by siRNA-3 oligos treatment, we
chose the siRNA-3 oligos for the next investigation. The
CCK8 analysis showed that LDHA knockdown cells exhibit-
ed significantly reduced cell viability compared with the neg-
ative control cells (Fig. 2b). The apoptosis assay showed that
cell apoptosis ratio was significantly increased after LDHA
was knocked down (Fig. 2c). And, consistent with this, the
caspase-3/7 activity was increased by LDHA siRNA treat-
ment (Fig. 2d). Next, to detect whether LDHA has an
Fig. 2 Silencing of LDHA by
siRNA inhibits cell proliferation,
migration, and invasion and
increases cell apoptosis in vitro. a
The expression level of LDHA
was detected by Western blotting
in PC-3 and DU145 cells after
three different siRNA treatment. b
Cell viability of PC-3 and DU145
cells was measured by CCK8 af-
ter LDHA knockdown. Increased
cell apoptosis ratio (c) and cas-
pase-3/7 activity (d) were ob-
served after LDHA knockdown.
Cell migration (e) and invasion
abilities (f) of PC-3 and DU145
cells were decreased after LDHA
was silenced. si-Ctrl versus si-
LDHA-3; *P<0.05; **P<0.01;
***P<0.001
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implication for cancer progression, cell migration and inva-
sion assays were performed. Migration assay showed that mi-
grated cells in siRNA-treated group was dramatically de-
creased in relative to the negative control group (Fig. 2e). In
the invasion assay, the invaded cells were also decreased sig-
nificantly after LDHA knockdown (Fig. 2f). Collectively, the-
se data above demonstrated that LDHA favors tumor growth
and metastasis in PC.
Inhibition of LDHA by FX11 suppresses cell proliferation,
migration, and invasion and increases cell apoptosis
in vitro
A small-molecule inhibitor, FX11 [3-dihydroxy-6-methyl-
7-(phenylmethyl)-4-propylnaphthalene-1-carboxylic acid]), is
a competitive inhibitor of LDHA. As tumor progression was
inhibited by siRNA-mediated LDHA reduction, here, we eval-
uated the effect of FX11 in PC-3 cells. As shown in Fig. 3a,
LDHA expression was not affected by FX11 treatment, indi-
cating that FX11 mainly affect the activities of LDHA. Consis-
tent with the results in siRNA-mediated reduction of LDHA,
attenuation of LDHA activities by FX11 also resulted in de-
creased cell viability (Fig. 3b), increased cell apoptosis
(Fig. 3c), increased caspase-3/7 activity (Fig. 3d), inhibition
of cell migration (Fig. 3e), and invasion (Fig. 3f). Taken togeth-
er, these results indicate that decreased LDHA enzyme activity
is also involved in the antitumor effect of FX11.
Inhibition of LDHA by siRNA or FX11 reprograms
glucose metabolism
Since LDHA executes the final step of aerobic glycolysis, we
postulated that LDHA-mediated functions in PC may associ-
ate with glucose metabolism. Expectedly, the lactate level in
the culture media was pronounced decreased after siRNA-
mediated LDHA knockdown (Fig. 4a) or FX11 treatment
(Fig. 4b). Besides, PC-3 cells also showed decreased glucose
consumption after whether siRNA-mediated LDHA knock-
down (Fig. 4c) or FX11 treatment (Fig. 4d). This data indicate
that enhanced glycolysis may account for the tumor-
suppressive effect of LDHA in PC.
Inhibition of LDHA by siRNA or FX11 downregulates
proteases involved in extracellular matrix degradation
and tumor metastasis
A critical consequence of altered lactate production and
secretion is the acidification of tumor microenvironment,
which favors the activation of a series of proteases, in-
cluding MMP-9, urokinase type plasminogen activator
(PLAU), and cathepsin B. And, this activation ultimately
induces extracellular matrix degradation and facilitates tu-
mor cells to metastasis. In our study, expression level of
MMP-9, PLAU, and cathepsin B was evaluated after
siRNA or FX11 treatment. Indeed, MMP-9, PLAU, and
Fig. 3 Inhibition of LDHA by
FX11 suppresses cell
proliferation, migration, and
invasion and increases cell
apoptosis in vitro. a The protein
level of LDHA in PC-3 cells after
FX11 treatment. b Cell viability
of PC-3 and DU145 cells was
measured by CCK8 after FX11
treatment. Increased cell apopto-
sis ratio (c) and caspase-3/7 ac-
tivity (d) were observed after
FX11 treatment. Cell migration
(e) and invasion abilities (f) of
PC-3 and DU145 cells were de-
creased after FX11 treatment. Ctrl
versus FX11; *P<0.05;
**P<0.01; ***P<0.001
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cathepsin B expression were remarkably decreased after
LDHA knockdown (Fig. 5a) or FX11 treatment
(Fig. 5b). In conclusion, these results support that
enhanced acidified microenvironment mediated by LDHA
promotes tumor cell metastasis, while increased utilization
of glucose facilitates tumor cell proliferation (Fig. 5c).
Fig. 5 Inhibition of LDHA by
siRNA or FX11 downregulates
proteases involved in extracellular
matrix degradation and tumor
metastasis. Relative expression of
MMP-9, PLAU, and cathepsin B
after LDHAwas knockdown (a)
or FX11 treatment (b). c
Schematic illustration of the
proposedmetabolic consequences
induced by LDHA in PC
Fig. 4 Inhibition of LDHA by
siRNA or FX11 reprograms
glucose metabolism. Relative
lactate secretion after LDHAwas
knockdown (a) or FX11 treatment
(b). Relative glucose
consumption after LDHAwas
knockdown (c) or FX11 treatment
(d). *P<0.05; **P<0.01; P
values were calculated by the
Student’s t test
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Discussion
In the present study, we observed overexpressed LDHA
in PC tissues compared with BPH tissues. By using two
PC cell lines, PC-3 and DU145, we asked whether the
elevated LDHA was essential for tumor progression and
whether LDHA altered tumor microenvironment that fa-
vors tumor growth or metastasis. To this end, we uti-
lized siRNA to suppress the expression of LDHA and
FX11 to inhibit LDHA enzyme activity. Our findings
demonstrated that enhanced glycolysis and acidified mi-
croenvironment induced by LDHA had a drastic impli-
cation on tumor physiology.
Given that the accelerated glucose metabolism distin-
guishes cancer cells from their normal counterparts, it is rea-
sonable to speculate that certain glycolytic enzymes are suit-
able to target for cancer therapy [12]. Many studies in tumors
aimed at LDHA confirm this point view [6, 13, 14]. Consis-
tent with previous reports, our results showed that knockdown
of LDHA or limiting the LDHA activity of PC cells is suffi-
cient to inhibit cell growth and metastasis [6, 9]. It is important
to emphasize here that although tumor biology was altered by
FX11 treatment, the LDHA enzyme activity was not measured
in our study. Whether alternations induced by FX11 were due
to decreased LDHA enzyme activity requires further
confirmation.
It was known that although Warburg effect produces re-
duced ATP compared with oxidative phosphorylation
(OXPHOS), it provides a constant supply of metabolites that
are essential for rapid macromolecule biosynthesis and neces-
sary for cell growth and division [15, 16]. Our results showed
that inhibition of LDHA significantly compromised cell via-
bility of PC-3 and DU145 cells and accompanied by a de-
crease in glucose consumption and lactate production. These
results, as a proof of principle, suggest a driver role of LDHA
in glycolytic activity in PC.
A critical consequence of Warburg effect is increased lac-
tate production by tumor cells. In cancer cells, lactate was
exported by monocarboxylate transporters resulting in the
acidification of microenvironment, whereas this alternations
leads to cell death in normal cells [17]. In our study, LDHA
deficiency led to a reduction in lactate production accompa-
nied by decreased cellular migration and invasion. Consistent
with this theory, our results confirmed that the expression of
proteases involved in extracellular matrix degradation includ-
ingMMP9, PLAU, and cathepsin Bwas reduced by inhibition
of LDHA. However, mechanism of this type of alternation in
proteases expression induced by LDHA inhibition remains
further demonstration.
In conclusion, our results from both clinical specimens and
in vitro cell experiments demonstrated that LDHA expression is
upregulated in PC, and it induces a favorable tumor microen-
vironment for tumor progression. We proposed that inhibition
of LDHA may represent a novel therapeutic strategy for con-
trolling metastasis as well as tumor growth in prostate cancer.
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